Evidence for the use of botulinum toxin in the chronic pain setting - A review of the literature

Pain Practice

Volumn 8, Issue 4, 2008, Pages 269-276

  Jeynes, Louise C ^a   Gauci, Charles A ^b,c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^c QUEEN S HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin; Cervical dystonia; Chronic pain; Evidence based medicine; Low back pain; Myofascial pain; Pelvic pain; Plantar fasciitis; Temporomandibular joint related facial pain

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; LIDOCAINE; LOCAL ANESTHETIC AGENT; PLACEBO; SODIUM CHLORIDE; STEROID; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ABSCESS; ACETYLCHOLINE RELEASE; ANALGESIA; ANAPHYLAXIS; ARTHRALGIA; CARPAL TUNNEL SYNDROME; CHRONIC PAIN; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; DIAPHRAGM PARALYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; EVIDENCE BASED MEDICINE; FACE PAIN; FLU LIKE SYNDROME; GENERAL PRACTITIONER; HOARSENESS; HUMAN; INHIBITION KINETICS; ISCHIALGIA; KINESIOTHERAPY; LOW BACK PAIN; MEDICAL LITERATURE; MUSCLE NECROSIS; MYOFASCIAL PAIN; NECK PAIN; NERVE COMPRESSION; NEUROPATHIC PAIN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT SELECTION; PELVIS PAIN SYNDROME; PHYSIOTHERAPY; PLANTAR FASCIITIS; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SCOLIOSIS; SHORT SURVEY; SORE THROAT; SPASMODIC TORTICOLLIS; SPASTICITY; TEMPOROMANDIBULAR JOINT DISORDER; TENNIS ELBOW; TREATMENT OUTCOME; WEAKNESS; WHIPLASH INJURY; XEROSTOMIA;

ANIMALS; BOTULINUM TOXINS; CHRONIC DISEASE; FOLLOW-UP STUDIES; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 48249154202     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00202.x     Document Type: Short Survey

References (100)

1. Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain. 2001;17:2-10.
2. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400-404.
3. Knutson GA. The role of the gamma-motor system in increasing muscle tone and muscle pain syndromes: A review of the Johansson/Sojka hypothesis. J Manipulative Physiol Ther. 2000;23:564-572.
4. Rosales RL, Arimura K, Takenga S, Osama M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin type A injection. Muscle Nerve. 1996;19:488-496.
5. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245-258.
6. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106-109.
7. Cui M, Aoki KR. Botulinum Toxin A reduces inflammatory pian in the rat formalin model. Cephalgia. 2000;20:414. Abstract 369.
8. Daemen MA, Kurvers HA, Kitslaar PJ, et al. Neurogenic inflammation in an animal model of neuropathic pain. Neurol Res. 1998;20:41-45.
9. Pedersen-Bjergaard U, Nielsen LB, Jensen K, et al. Calcitonin gene-related peptide, neurokinin A and substance P: Effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides. 1991;12:333-337.
10. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia. 1995;15:277-280.
11. Kandel ER, Schwartz JH, Jessel TM. Principles of Neural Science, 4th edn. New York: McGraw-Hill; 2001.
12. Berardelli A, Gilo F, Curra A. Effects of botulinum toxin type A on central nervous system function. In: Brin MF, Jankovic J, Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Wi l liams & Wilkins; 2002:171-177.
13. Byrnes ML, Thickbroom GW, Wilson SA, et al. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain. 1998;121:977-988.
14. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Art. No.: CD003633. 10.1002/ 14651858.CD003633.pub2
15. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Art. No.: CD004315. DOI: 10.1002/ 14651858.CD004315.pub2?B
16. Freund BJ, Schwartz M. Use of botulinum toxin in whiplash-associated disorder. Clin J Pain. 2002;18(suppl 6):S163-S168.
17. Pradberg M, De Brujin SFTM, Tavy DLJ. Neck pain in whiplash syndrome treated with botulinum toxin. A double-blind placebo-controlled clinical trial. J Neurol. 2007;254:290-295.
18. Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain. 2007;11:519-527.
19. Pereda CA, Uson Jaeger J, Carmona L. Systematic review: Can botulinum toxin be recommended as treatment for pain in myofascial syndrome? Reumatologia. 2006;2:173-182.
20. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport Myofacial Pain Study Group. Efficacy and safety of a single botulinum type A toxin complex treatment for the relief of upper back myofascial pain syndrome: Results from a randomised double-blind placebo controlled multicentre study. Pain. 2006;125:82-88.
21. Kumar A, Azad R, Ahuja S, Sethi AK. World congress pain handbook. In: IASP Scientific Programme Committee, eds. Abstract: 11th World Congress on Pain, August 21-26, 2005, Sydney, Australia. Seattle, WA: IASP; 2005: ABS 1246 p. 16.
22. Nalamachu S. An open-label assessment of botulinum toxin type A versus anaesthetic-steroid combination in the treatment of cervicothoracic myofascial pain. Arch Phys Medical Rehabil. 2005;86:E34 ABS-Poster 164.
23. Lang AM. Botulinum toxin type A for the management of cervicothoracic and cervicobrachial pain: Treatment rationale and open-label results in 25 patients. Am J Pain Manage. 2004;14:13-23.
24. Taqi D, Gunyea I, Bhakta B, et al. Botulinum toxin type A in the treatment of refractory cervicothoracic myofascial pain. Pain Med. 2002;3(2):173-174.
25. De Andrés J, Cerdo-Olmedo G, Valia JC, Monsalve V, Lopez-Alarcon MD, Minguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. 2003;19:269-275.
26. Graboski CL, Gray DS, Burnham RS. Botulinum toxin a versus bupivicaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double-blind crossover study. Pain. 2005;118:170-175.
27. Ojala T, Arokoski JPA, Partanen J. The effect of small doses of botulinum toxin on neck-shoulder myofascial pain syndrome: A double-blind, randomised and controlled crossover trial. Clin J Pain. 2006;22:90-96.
28. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. 2006;67:241-245.
29. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005;103:377-383.
30. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Ozkurt-Zengin F, Bayik Y. Comparison of lidocaine injection, botulinum injection and dry needling to trigger points in myofascial syndrome. Rheumatol Int. 2005;25:604-611.
31. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome. Am J Phys Med Rehabil. 2002;81:751-759.
32. Stenner A, Reichel G, Hermann W. Piriformis syndrome: Successful treatment with botulinum toxin A. Mov Disord. 2006;21(suppl 15):S428 ABS-P365.
33. Yoon SJ, Ho J, Kang HY, et al. Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. Pharmacotherapy. 2007;27:657-665.
34. Betts A. Combined fluoroscopic and nerve stimulator technique for injection of the piriformis muscle. Pain Physician. 2004;7:279-281.
35. Reichel G, Stenner A. Piriformis syndrome treated successfully with botulinum toxin in 22 patients. J Neurol. 2004;251(suppl 1): I/47 A7.
36. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. 2004;83:198-202.
37. Saleemi S. Treatment of piriformis muscle syndrome with botulinum toxin-A. Am Soc Anesth. 2002;96 A879.
38. Fanucci E, Masala S, Sodani G, etal. CT-guided injection of botulinum toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MRI results about denervation process. Eur Radiol. 2001;11:2543-2548.
39. Porta M, Maggioni G. Botulinum toxin and back pain. J Neurol. 2004;251(suppl 1):I/15-I/18.
40. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002;18:S155-S162.
41. Jost W, Reilich P, Pongratz D. Botulinum toxin in low back pain. In: Jost WH, ed. Botulinum Toxin in Painful Diseases Pain and Headache. Basel: Karger AG CH 4009; 2003:159-169.
42. Nurmikko TJ. Management of pain with botulinum toxin. In: Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment. Oxford, UK: Blackwell Publishing; 2003:404-421.
43. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. A randomized, double-blind study. Neurology. 2001;56:1290-1293.
44. Knusel B, DeGryse R, Grant M, et al. Intramuscular injection of botulinum toxin type A (BOTOX) in chronic low back pain associated with muscle spasm. American Pain Society Annual Meeting, 1998.
45. Edwards K. Botulinum toxin type A for failed back syndrome. J Pain. 2005;6(3 suppl1):S39 ABS-725.
46. Dunteman E. Chronic low back pain treatment with botulinum toxin type A. J Pain. 2003;4(2 suppl 1):87 ABS 941.
47. Paulin M. Botulinum toxin A motor nerve blocks in the treatment of back pain. J Pain. 2003;4(2 suppl 1):88 ABS 946.
48. Carrasco AT, Wescoat L, Roman A. A retrospective review of botulinum toxin type A compared with standard therapy in the treatment of lumbar myofascial back pain patients. Pain Clinic. 2003;15:205-211.
49. Edwards K, Dreyer M. Botulinum toxin A (Botox) for refractory low back pain. J Pain. 2003;4(2 suppl 1):28 ABS 710.
50. Aglan M, Croach-Harvey M, Sokil C. Botulinum toxin type A injection of the iliopsoas muscle for the treatment of low back pain and sciatica. J Pain. 2003;4(2 suppl 1):25 ABS 695.
51. Alo KM, Yland MJ, Kramer DL, Charnov JH, Redko V. Botulinum toxin in the treatment of myofascial pain. Pain Clinic (Pein Kurinikku). 1997;10:107-116.
52. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: Successful treatment with botulinum toxin injections. Mov Disord. 1998;13:552-555.
53. Subin B, Morgan-First GA, Cork RC. Treatment of chronic low back pain by local injection of botulinum toxin A. Anesthesiology. 2002;97:ABS A-771.
54. Cannard KR, Ales GD, DiFazio MP, Spencer NA, Ling GS, Jabbari R. The efficacy of botulinum toxin A as treatment for chronic low back pain secondary to trauma or strain injury. Neurology. 2005;64(suppl 1):A120 ABS-P02. 151.
55. Foldyna A, Pacejka M, Ulc I. Botulinum toxin in therapy of back pain-Fibromyalgic syndrome (CZE). Rehabilitacia. 2005;42:91-93.
56. Chevlen E. Double-blind placebo-controlled study of intradermal botulinum toxin A in chronic pain. J Pain. 2005;6(3 suppl 1):S40 ABS-727.
57. Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: An open-label, pilot study. Pain Med. 2006;7:260-264.
58. Ney JP, Difazio M, Sichani A, Monacci W, Foster L, Jabbari B. Treatment of chronic low back pain with successive injections of botulinum toxin A over 6 months: A prospective trial of 60 patients. Clin J Pain. 2006;22:363-369.
59. Abbott JA, Jarvis SK, Lyons S, Thomson A, Vancaillie TG. Botulinum toxin A for chronic pain and pelvic floor spasm in women: A randomised controlled trial. Obstetrics Gynaecology. 2006;108:915-923.
60. Yoon H, Chung W, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impotence Res. 2007;19:84-87.
61. Gunter J, Brewer A, Tawfik O. Botulinum toxin A for vulvodynia: A case report. J Pain. 2004;5:238-240.
62. Gajraj NM. Botulinum toxin A injection of the obturator internus muscle for chronic perineal pain. J Pain. 2005;6:333-337.
63. Merideth M, Karp B, Bartrum E, Zimmer C, Stratton P. Botulinum toxin in the treatment of chronic pelvic pain and endometriosis. J Soc Gynecol Invest. 2006;13(suppl 2):276A ABS-644.
64. Dykstra DD, Presthus J. Botulinum toxin A for the treatment of provoked vestibulodynia: An open-label, pilot study. J Reprod Med. 2006;51:467-470.
65. El-Hakim A. Chronic prostatitis/chronic pelvic pain syndrome: Is there a role for local drug infiltration therapy. J Endourol. 2004;18:227-231.
66. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin A: A short-term, randomised, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005;84:649-654.
67. Placzek R, Deuretzbacher G, Nat R, Meiss AL. Treatment of chronic plantar fasciitis with botulinum toxin A. Preliminary clinical results. Clin J Pain. 2006;22:190-192.
68. Wong SM, Hui ACF, Tong PY, Poon DWF, Yu E, Wong LKS. Treatment of lateral epicondylitis with botulinum toxin: A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143:793-797.
69. Hayton MJ, Santini AJA, Hughes PJ, Frostick SP, Trail IA, Stanley JK. Botulinum toxin injection in the treatment of tennis elbow: A double-blind, controlled, pilot study. J Bone Joint Surg [Am]. 2005;87A:503-507.
70. Placzek R, Lindner MS, Deuretzbacher G, Meiss AL. Botulinum toxin A injection for chronic tennis elbow: A potential new mode of treatment. Pain Clinic. 2005;17:133-138.
71. Keizer SB, Rutten HP, Pilot P, Morre HH, vOs JJ, Verburg AD. Botulinum toxin injections versus surgical treatment for tennis elbow: A randomised pilot study. Clin Orthop Relat Res. 2002;401:125-131.
72. Placzek R, Meiss L. Temporary chemical denervation with botulinum toxin A in epicondylitis radialis-a therapy trial in 14 patients. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl. 2):R34.
73. Bluthner M, Haugke C, Kalischewski P. Treatment of lateral epicondylitis elbow with botulinum toxin A-a first experience. Arch Pharmacol. 2002;365(suppl 2):R14 ABS- 21.
74. Singer BJ, Silbert PL, Dunne JW, Song S, Singer KP. An open label pilot investigation of the efficacy of botulinum type A injection in the rehabilitation of chronic anterior knee pain. Disab Rehabil. 2006;28:707-713.
75. Mahowald ML, Singh AA, Dykstra D. Long term effects of intra-articular botulinum A toxin for refractory joint pain. Arthritis Rheum. 2004;50:(Suppl 9):S454 ABS-1147.
76. Seedorf H, Leuwer R, Bussopulos A, Fenske C, Jüde HD. Influence of botulinum toxin on myogenous facial pain. Schmerz. 2005;19:18-25.
77. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18:S198-S203.
78. Lee KM, Chow J, Hui E, Li W. Botulinum toxin type A for the management of myofascial temporomandibular pain disorder. Asian J Oral Maxillofacial Sur. 2005;17:100-103.
79. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465.
80. Piovesan EJ, Teive HG, Kowacs PA, Della Colleta MV, Werneck LC, Silberstein SD. An open study of botulinum toxin treatment of trigeminal neuralgia. Neurol. 2005;65:1306-1308.
81. Volcy M, Tepper S, Rapoport AM, Sheftell FD, Bigal ME. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia. A case report with pathophysiological considerations. Cephalalgia. 2005;25:990.
82. Turk U, Ilhan S, Alp R, Surt I. Botulinum toxin for intractable trigeminal neuralgia. Clin Neuropharmacol. 2005;28:161-162.
83. Allam N, Brasil-Neto JP, Brown G, Tomaz C. Injection of botulinum toxin type A producing pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005;21:182-184.
84. Ko J. Botulinum toxin-A alleviates trigeminal and post-herpetic neuralgia facial pain. Muscle Nerve. 2004;30:540 ABS.
85. Lui HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin-A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7:89-91.
86. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg. 2004;30:452-455.
87. Wittekindt C, Liu WC, Preuss SF, Guntinas-Lichius O. Botulinum toxin A for neuropathic pain after neck dissection: A dose finding study. Laryngoscope. 2006;116:1168-1171.
88. Kern U. Influence of botulinum toxin on post-amputation pain and phantom limbs. J Neurol. 2004;251(suppl 1):A6.
89. Kern U, Martin C, Scheicher S, Muller H. Long term treatment of phantom and stump pain with type A botulinum toxin for 1 year. First clinical observations. Nervenarzt. 2004;75:336-340.
90. Tiwari A, Singh A, Verma RK, Rastogi V, Agrawal R. Botulinum toxin in the management of neuroma pain: Case report. The Pain Clinic. 2006;18:263-265.
91. Kamen LB. Botulinum toxin type B for treatment of neuromuscular pain associated with brachial plexopathy. Poster presentation at the Annual Scientific Meeting of the American Pain Society, Baltimore, March 2001.
92. Cordivari C, Misra PV, Catania S, Less AJ. Treatment of dystonic clenched fist with botulinum toxin. Movement Disorders. 2001;16:907-913.
93. Rocha LG, Dos Santos VF, De Mattos AL. Functional rehabilitation and analgesia with botulinum toxin A in upper limb complex regional pain syndrome type 1. Case reports. Revista Brasileira Anestesiologia. 2005;55:207-211.
94. Morelet A, Gagneux-Lemoussu L, Brochot P, et al. Tonic dystonia: An uncommon complication of reflex sympathetic dystrophy syndrome. A review of five cases. Jt Bone Spine. 2005;72:260-262.
95. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18(suppl 6):S177-S181.
96. Breuer B, Sperber K, Wallenstein S, et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpel tunnel syndrome. Pain Med. 2006;7:16-24.
97. Racz GB. Botulinum toxin as a new approach for refractory pain syndromes. Pain Digest. 1998;8:355-358.
98. Puehler W, Brack A, Kopf A. Extensive abscess formation after repeated paravertebral injections for the treatment of chronic back pain. Pain. 2005;113:427-429.
99. Hogan KA, Manning EL, Glaser JA. Progressive cervical kyphosis associated with botulinum toxin injection. Southern Med J. 2006;99:888-891.
100. Agaba AE, Mahmoud S, Esmail H, Sutton J, Bertalot JC, Jibani MM. Extensive myofascial necrosis: A delayed complication of botulinum toxin therapy. Eur J Intern Med. 2005;16:603-605.